W
William H. Bunnelle
Researcher at AbbVie
Publications - 65
Citations - 1766
William H. Bunnelle is an academic researcher from AbbVie. The author has contributed to research in topics: Nicotinic agonist & Agonist. The author has an hindex of 24, co-authored 65 publications receiving 1727 citations.
Papers
More filters
Journal ArticleDOI
Broad-Spectrum Efficacy across Cognitive Domains by α7 Nicotinic Acetylcholine Receptor Agonism Correlates with Activation of ERK1/2 and CREB Phosphorylation Pathways
Robert S. Bitner,William H. Bunnelle,David J. Anderson,Clark A. Briggs,Jerry J. Buccafusco,Peter Curzon,Michael W. Decker,Jennifer M. Frost,Jens Halvard Grønlien,Earl J. Gubbins,Jinhe Li,John Malysz,Stella Markosyan,Kennan C. Marsh,Michael Meyer,Arthur L. Nikkel,Richard J. Radek,Holly M. Robb,Daniel B. Timmermann,James P. Sullivan,Murali Gopalakrishnan +20 more
TL;DR: It is demonstrated that α7 nAChR agonism can lead to broad-spectrum efficacy in animal models at doses that enhance ERK1/2 and CREB phosphorylation/activation and may represent a mechanism that offers potential to improve cognitive deficits associated with neurodegenerative and psychiatric diseases, such as Alzheimer's disease and schizophrenia.
Journal ArticleDOI
In vivo pharmacological characterization of a novel selective α7 neuronal nicotinic acetylcholine receptor agonist ABT-107: Preclinical considerations in Alzheimer's Disease
R. Scott Bitner,William H. Bunnelle,Michael W. Decker,Karla Drescher,Kathy L. Kohlhaas,Stella Markosyan,Kennan C. Marsh,Arthur L. Nikkel,Kaitlin E. Browman,Rich Radek,David J. Anderson,Jerry J. Buccafusco,Murali Gopalakrishnan +12 more
TL;DR: The findings show that targeting α7 nAChRs may have potential utility for symptomatic alleviation and slowing of disease progression in the treatment of AD, and expand the understanding of the potential therapeutic viability associated with the α7NAChR approach.
Journal ArticleDOI
Design of ligands for the nicotinic acetylcholine receptors: the quest for selectivity.
TL;DR: An overview of the structure-affinity relationships that continue to drive development of new nAChR ligands is provided.
Journal ArticleDOI
Preclinical Characterization of A‐582941: A Novel α7 Neuronal Nicotinic Receptor Agonist with Broad Spectrum Cognition‐Enhancing Properties
Karin R. Tietje,David J. Anderson,R. Scott Bitner,Eric A.G. Blomme,Paul J. Brackemeyer,Clark A. Briggs,Kaitlin E. Browman,Dagmar Bury,Peter Curzon,Karla Drescher,Jennifer M. Frost,Ryan M. Fryer,Gerard B. Fox,Jens Halvard Grønlien,Monika Håkerud,Earl J. Gubbins,Sabine Halm,Richard Harris,Rosalind J. Helfrich,Kathy L. Kohlhaas,Devalina Law,John Malysz,Kennan C. Marsh,Ruth L. Martin,Michael Meyer,Angela L. Molesky,Arthur L. Nikkel,Stephani Otte,Liping Pan,Pamela S. Puttfarcken,Richard J. Radek,Holly M. Robb,Eva Spies,Kirsten Thorin-Hagene,Jeffrey F. Waring,Hilde Ween,Hongyu Xu,Murali Gopalakrishnan,William H. Bunnelle +38 more
TL;DR: Preclinical validation that α7 nAChR agonism offers a mechanism with potential to improve cognitive deficits associated with various neurodegenerative and psychiatric disorders is provided.
Journal ArticleDOI
Selective amination of polyhalopyridines catalyzed by a palladium-xantphos complex.
TL;DR: Amination of 5-bromo-2-chloropyridine catalyzed by a palladium-Xantphos complex predominately gives 5-amino-2/4a in 96% isolated yield and excellent chemoselectivity.